NOV 0 1 2004

DATE:

October 29, 2004 SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF CHANGE CE (Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

5967.US.C1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Maurice Cohen, et al.

GROUP

(Use several sheets if necessary)

FILING DATE
January 22, 2004

1642

(37 CFR 1.98 (b))

U.S.PATENT DOCUMENTS

								ISSUE		j	SUB	FILING
	:	PATENT NUMBER					3	DATE	PATENTEE	CLASS	CLASS	DATE
	<u> </u>							<u></u>				
Al	4	6	8	3	1	9	5	7/28/87	Mullins, et al.			
A2	4	6	8	3	2	0	2	7/28/87	Mullins, et al.	- 		
A3	5	3	2	2	7	7	0	6/21/94	Gelfand, et al.			
A4	5	1	8	5	4	4	4	2/9/93	Summerton, et al.			
A5	5	0	3	4	5	0	6	7/23/91	Summerton, et al.			
A6	5	ī	4	2	0	4	7	8/25/92	Summerton, et al.			
A7	5	5	1	6	6	6	3	5/14/96	Backman, et al.			
A8	5	2	9	0	9	2	5	3/1/94	Fino			
A9	5	9	1	9	6	3	8	07-1999	Russell, et al.			
	A2 A3 A4 A5 A6 A7 A8	A1 4 A2 4 A3 5 A4 5 A5 5 A6 5 A7 5 A8 5	A1 4 6 A2 4 6 A3 5 3 A4 5 1 A5 5 0 A6 5 1 A7 5 5 A8 5 2	A1	A1	A1	A1	A1	A1	A1	A1	A1

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

			DO	 OCL	JME	NT	NU	мв	ER	PUBLI- CATION		ANS- TION
	1									DATE	PATENT OFFICE CLASS CLASS YES	
	\mathbf{X}	BI	0	3	2	0	3	0	8	14.06.89	P	T
	X	B2	0	4	3	9	1	8	2	31.07.91		
	$i \times I$	B3	0	4	5	4	6	1	0	30.10.91		
		B4	0	6	7	9	7	1	6	02.1995		
		B4	0	6	8	4	3	1	5	29.11.95		<u> </u>
		B5	9	3	2	2	4	6	1	29.04.93	0	
		B6	9	2	2.	0	7	0	2	26.11.92	0	
		B7	9	2	1	0	5	0	5	25.06.92	0 , ,	
		B8	9	2	l	1	3	8	8	09.07.92	0	
		B9	8	4	0	3	5	6	4	09.13.94	0	<u> </u>
		B10	0	6	5	5	4	9	8	13.05.95		
		B11	9	6	2	3	0	7	9	01.08.96	0	
		B12	9	6	2	1	0	4	2	11.07.96	0	
/V		B13	9	5	2	8	4	9	8	26.10.95	0	
		B14	9	5	2	0	6	8	1	03.08.95	0	

	C	THER DOCUMENTS (Including	Author, Title, Date, Place of Publication)									
	Cl	Athauda, et al., "Entrapment and Inhibition of Human Immunodeficiency Virus Proteinase by a-Macroglobulin and										
MX		Structural Changes in the Inhibitor", Journ of Biochemistry, 113:742-746 (1993)										
	C2	Braxton, S., et al., "Incorporation of a Stabilizing CA2+-Binding Loop into Subtilisin BPN", Biochemistry, 31:7796-7801 (1992)										
EXAMINER			DATE CONSIDERED									
	Du	Ral.	7/12/05									
EXAMINER:	EXAMINER: Initial citation considered. Draw line through citation if not in conformance and											
not considere	not considered. Include copy of this form with next communication to applicant.											

(Form PTO-1449)

October 29, 2004 DATE: SHEET 2 of 3 Form PTO - 1449 (Modified) FORM PTO-1449 U.S. DEPARTMENT OF ATTY. DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE (Modified) 5967.US.C1 APPLICANT INFORMATION DISCLOSURE Maurice Cohen, et al. STATEMENT BY APPLICANT FILING DATE GROUP (Use several sheets if necessary) 1642 January 22, 2004 (37 CFR 1.98 (b))

U.S.PATENT DOCUMENTS

EXAMINER									ISSUE	,		SUB	FILING
INITIAL	Ì	PATENT NUMBER					BER	t	DATE	PATENTEE	CLASS	CLASS	DATE
						Г							

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUME	ENT	NUM	BER	PUBLI- CATION	COUNTRY OR	·	SUB	TRANS- LATION		
					DATE	PATENT OFFICE	CLASS	CLASS	YES	NO	
		ΓΠ				·			·		

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

0	C3	Compton, J., "Nucleic acid sequence-based amplification", Nature, 350:91-92 (1991)
4.1	C4	Cooney, M., et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human C-myc Gene in
IXI		Vitro", Science, 241:456-459 (1988)
4	C5	Dervan, B., et al., "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix
Γ		Formation", Science, 251:1360-1366 (1991)
- I	C6	Guatelli, J. C., et al., "Isothermal, In vitro amplification of nucleic acids by a multienzyme reaction modeled after
	<u>l. </u>	retroviral replication", PNAS, 87:1874-1878 (1990)
	C7	Hanks, et al., "Cancer of the Prostate", Cancer Principles & Practice of Oncology, 1(4th Edit.):1073-1113 (1993)
	C8	Hillier, et al., Ac. No. HS835158, July 1995, XP002053784
	C9	Hillier, et al., AC. No. HS836158, July 1995, XP002053785
	C10	Hillier, et al., Ac. No. HS660266, January 1996, XP002053786
	C11	Hillier, et al., EMBL N31660 (1995)
	C12	Hodgson, J., "Data-Directed Drug Design", Biotechnology, 9:12-21 (1991)
	C13	Hudson, et al., EMBL G22461 (1995)
	C14	Jacobs, et al., "Clinical Use of Tumor Markers in Oncology", Curr. Prob. Cancer, 299-350 (1991)
	C15	Lee, J. S., et al., "Complexes formed by (pyrimidine), (purine), DNAs on lowering the pH are three-stranded",
1		Nucleic Acids Research, 6(9):3073-3091 (1979)
	C16	Marshall, R. L., et al., "Detection of HCV RNA by the Asymmetric Gap Ligase Chain Reaction", PCR Methods and
		Applications, 4:80-84 (1994)
	C17	Matsubara, et al., AC. No. T25991, October 1996, XP002053788
	C18	Okano, H., et al., "Myelin Basic Protein Gene and the Function of Antisense RNA in its Repression in Myelin-
		Deficient Mutant Mouse", Journ of Neurochemistry, 56:560-567 (1991)
1	C19	Pantel, et al., "Methods for Detection of Micrometastatic Carcinoma Cells in Bone Marrow, Blood and Lymph
	-	Nodes", Onkologie, 18:394-401 (1995)
	C20	Schwartz, M. K., "Cancer Markers", Principles & Practice of Oncology, 1(4th Edicition):531-542 (1993)
W	C21	Thuong, N. T., et al., "Solid Phase Synthesis of Oligo-a- and Oligo-b-Deoxynucleotides Covalentyly Linked to an
\		Acridine", Tetrahedron Letters, 29(46):5905-5908 (1988)
EXAMINER	M	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTC) - 144	9 (Mod	lified	I)	HOV O	TOTA E D	ATE: October 🔏	<u>(9</u> , 2004	SHEET	_3_ 0	f_3			
FORM PTO-				SITE OF	Coam		ATTY DOCUET NO	CEDY						
(Modified)	P	ATENT.	AND 1	TRADE	MARK	OFFICE	ATTY. DOCKET NO.	SERIA	SERIAL NO.					
							5967.US.C1							
	IN	FORMA	TION	DISCL	OSURI	Ε	APPLICANT							
	SI	CATEME	ENT B	Y APPL	ICANT	ſ	Maurice Cohen, et							
	a	Jse sever	al cha	ats if nas	المحدم		FILING DATE	JP						
(37 CFR 1.98	-	J36 36461	a1 311€	ers ii nec	essai y)		January 22, 2004	1642	1642					
,					τ	J.S.PATENT	DOCUMENTS							
EXAMINER	Ţ	γ	-			ISSUE		<u> </u>	SUB	FILE	FILING			
INITIAL		PA1	ENT	NUMB	ER	DATE	PATENTEE	CLASS	CLASS	DA				
	FO	REIG	N PA	ATEN	ΓOR	PUBLISHE	D FOREIGN PATENT	APPLICA	TION					
						PUBLI-					ANS-			
		DOCL	JMEN	IT NUM	IBER	CATION	COUNTRY OR		SUB	<u> </u>				
		ļ , ,				DATE	PATENT OFFICE	CLASS	CLASS	YES	NC			
		Ll		_				_L	L	L				
		OTF	IER	DOCU	JMEN	NTS (Including	g Author, Title, Date, Place	of Publication	n)					
Cal D	C22						amplification (SDA) and transier		ence polariza	tion				
	C23						DNA", Clinical Chemistry, 42:9-1 5, XP002053787	3 (1996)						
- 41/	C24						genic Determinant in a Protein",	Coll 37.767-7	78 (1984)		—			
+V-	C25						nucleotides as Antisense Inhibitor			8)				
	C26						Publishers, NY pg. 335 & 343 (1		• (170	",				
	1	 				,, = ==,,		,			—			
														
						_								
	1													

DATE CONSIDERED

(Form PTO-1449)

EXAMINER: Initial citation considered. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER